Role of molecular markers in the management of head and neck cancers

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 259-264

  Ferreira, Mariana B ^a   De Souza, Jonas A ^b   Cohen, Ezra E W ^b,c  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF CHICAGO   (United States)

^c 900 East 57th Street ^*  (United States)

Author keywords

cancer; epidermal growth factor receptor; head and neck; human papillomavirus; molecular markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUMOR MARKER;

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEAD AND NECK CARCINOMA; HUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR CLASSIFICATION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955028238     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328344f53a     Document Type: Review

References (32)

1. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multiinstitutional experience. Ann Oncol 2004; 15:1179-1186. (Pubitemid 39199304)
2. Bourhis J, Le Maitre A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19:188-194. (Pubitemid 46597476)
3. Posner MR, HershockDM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. (Pubitemid 350005152)
4. Bozec A, Gros F-X, Penault-Llorca F, et al. Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008; 13:1922-1930.
5. Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009; 1:36.
6. Hayes DF, Bast R, Desch CE, et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88:1456-1466. (Pubitemid 26340047)
7. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008; 54:1770-1779.
8. Iwase M, Takaoka S, Uchida M, et al. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol 2008; 4:361-368. (Pubitemid 351380981)
9. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39:1348-1354. (Pubitemid 36773776)
10. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohis-tochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996; 78:1284-1292. (Pubitemid 26303896)
11. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13:132-139.
12. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11:1873-1878. (Pubitemid 23304610)
13. BonnerJA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximabforsquamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. (Pubitemid 43209104)
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28.
15. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resis tance to EGFR targeting. Clin Cancer Res 2006; 12:5064-5073. (Pubitemid 44453332)
16. Chen LF, Cohen EEW, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16:2489-2495.
17. Harrington KJ, Kazi R, Bhide SA, et al. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian J Cancer 2010; 47:248-259.
18. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995; 6: 1251-1259.
19. Pectasides E, Fountzilas G, Kountourakis P, et al. Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (SCCHN) using AQUA. J Clin Oncol (Meeting Abstracts) 2010; 28 (Suppl 15):5538.
20. Klozar J, Tachezy R, Rotnaglova E, et al. Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. Wien Med Wochenschr 2010; 160:305-309.
21. Heck JE, Berthiller J, VaccarellaS, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010; 39:166-181.
22. Smith EM, Rubenstein LM, Haugen TH, et al. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control 2010. [Epub ahead of print]
23. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527. (Pubitemid 36159887)
24. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15:6758-6762.
25. Machado J, Reis PP, Zhang T, et al. Low prevalence of human papillomavirus in oral cavity carcinomas. Head Neck Oncol 2010; 2:6.
26. Shuman AG, Wolf GT. Human papillomavirus status in head and neck cancer. Cancer 2010; 116:4221-4226.
27. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010; 46:492-496.
28. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papilloma-virus-induced oncogenesis. J Virol 2004; 78:11451-11460.
29. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13:139-168. (Pubitemid 24220002)
30. Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemo- sensitization and chemoprevention. Curr Mol Pharmacol 2010. [Epub ahead of print]
31. Marsh S. Pharmacogenomics. Ann Oncol 2007; 18 (Suppl 9):ix24-ix28.
32. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-708. (Pubitemid 24251002)